CR2 and acute lymphoblastic leukemia: Despite this, we show that anti-CD21 CAR-T cells targeting membrane-proximal epitopes and using an antigen-binding fragment (Fab) antigen-binding domain have robust in vitro and in vivo antitumor activity in multiple T-ALL models.